Eine gute Nachricht für Hautkrebspatienten, eine Einstiegschance für Anleger: Der US-Konzern präsentiert vielversprechende ...

Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...

Moderna launched its coronavirus vaccine in early pandemic days and saw revenue and stock performance skyrocket. As demand ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

Can AI help us fight cancer more effectively? Moderna is putting that promise to the test, using AI to help design ...

A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna ...

The Food and Drug Administration has refused to start a review of Moderna's application for its experimental flu shot, the company said. It's another sign of the Trump administration's influence on ...

Succès clinique du vaccin anticancéreux de Moderna et Merck contre le mélanome, mais Wall Street sanctionne : médecine, coûts ...

Dopo il boom grazie al farmaco anti-Covid, l’azienda Usa è tornata a crescere grazie all'oncologia. L’analisi degli esperti ...

Leaked data from Moderna Inc. and Merck & Co.’s highly anticipated melanoma vaccine trial has led to a rare disconnect ...

Berenberg sube el precio objetivo de Moderna hasta los 100 dólares por acción desde los 45 dólares por título previos tras los resultados positivos de su vacuna con Merck contra el melanoma, aunque ...

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top ...